Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,198 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Completed Phase 2 Interventional Results available

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

NCT00101413
View directory record Official record
Conditions
Cancer, Carcinoma, Non-Small Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 22, 2026, 7:16 PM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00104780
View directory record Official record
Conditions
Lung Cancer
Interventions
EP-2101, incomplete Freund's adjuvant
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
9
States / cities
Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Genetic Predictors of Benefit to Pembrolizumab

NCT02710396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00070486
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, gemcitabine hydrochloride, zileuton
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
75
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 22, 2026, 7:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

NCT03433469
View directory record Official record
Conditions
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Interventions
Osimertinib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Davis, California • San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

NCT00004879
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

NCT03982459
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Decision support tool
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)

NCT02019979
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions
metformin, carbohydrate restricted diet
Drug · Behavioral
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 22, 2026, 7:16 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluating the Feasibility and Preliminary Effects of BE+

NCT07214441
View directory record Official record
Conditions
Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity, Stress, Quality of Life, Resistance Training
Interventions
Breathe Easier+
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

NCT01948141
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
nintedanib
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

NCT04199741
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3, SC16.56, Phase II
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

NCT01757288
View directory record Official record
Conditions
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Interventions
NAB-PACLITAXEL, PACLITAXEL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Rochester, New York • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Durvalumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
38
States / cities
Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting Phase 1 Interventional

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

NCT04615013
View directory record Official record
Conditions
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
Interventions
Capecitabine, Carboplatin, Docetaxel, Fluorouracil, Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Paclitaxel
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 1 Interventional Results available

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

NCT00424840
View directory record Official record
Conditions
Lung Cancer
Interventions
Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting No phase listed Observational

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Monterey, California • Torrance, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Withdrawn Phase 1 Interventional

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

NCT05358691
View directory record Official record
Conditions
Lung Cancer Stage III
Interventions
AN0025
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting Phase 2 Interventional

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

NCT04933903
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

NCT00400803
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Gemcitabine, Carboplatin, Bevacizumab
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

NCT01831089
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions
PM01183 + paclitaxel +/- bevacizumab
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

NCT01797159
View directory record Official record
Conditions
Small-cell Lung Cancer, SCLC, Small Cell Lung Cancer Limited Stage
Interventions
Hippocampal-sparing Prophylactic Cranial Irradiation
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Physical Activities by Technology Help (PATH)

NCT03212079
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions
Mycoach Smart Text, MyCoach on Amazon Alexa
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

NCT00097903
View directory record Official record
Conditions
Carcinoma, Carcinoma, Non-Small-Cell Lung
Interventions
Karenitecin (BNP1350)
Drug
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 7:16 PM EDT